Announcements Trials
Browse Landscape

Phase

Phase 1 3

Status

Completed 3Terminated 1Suspended 1Recruiting 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Other hematologic neoplasm 3Myeloid 2Lymphoid 2Plasma cell 1

Conditions

Melanoma 57Carcinoma, Renal Cell 19Leukemia, Myeloid, Acute 15Lymphoma, Non-Hodgkin 10Leukemia 10Kidney Neoplasms 10Skin Neoplasms 9Neuroblastoma 9Neoplasms 9Neoplasm Metastasis 9Lymphoma 9Breast Neoplasms 7Leukemia, Lymphocytic, Chronic, B-Cell 6Recurrence 5Precursor Cell Lymphoblastic Leukemia-Lymphoma 5Ovarian Neoplasms 5Myelodysplastic Syndromes 5Congenital Abnormalities 5Uveal Melanoma 4Multiple Myeloma 4Lymphoma, Mantle-Cell 4Lymphoma, Follicular 4Leukemia, Myelogenous, Chronic, BCR-ABL Positive 4Hodgkin Disease 4Hematologic Neoplasms 3Fallopian Tube Neoplasms 3Carcinoma, Non-Small-Cell Lung 3Carcinoma, Hepatocellular 3Uterine Cervical Neoplasms 2Unspecified Adult Solid Tumor, Protocol Specific 2

Interventions

Cyclophosphamide 32Tacrolimus 29fludarabine 27Mycophenolic Acid 23fludarabine phosphate 22Busulfan 19Whole-Body Irradiation 18Melphalan 16Methotrexate 15Antilymphocyte Serum 14Rituximab 12Bortezomib 11Stem Cell Transplantation 10Cyclosporine 10thymoglobulin 9Sirolimus 9Granulocyte Colony-Stimulating Factor 9Peripheral Blood Stem Cell Transplantation 8Thiotepa 7Interviews as Topic 7Filgrastim 7Dexamethasone 7Clofarabine 7Blood Specimen Collection 6Alemtuzumab 6merphos 5Voriconazole 5Standard of Care 5Nivolumab 5Lenalidomide 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Completed × Hematologic Neoplasms × Interleukin-2 × Clear all
NCT04634435 2025-01-20

Autologous Memory-like NK Cell Therapy With BHV-1100 and Low Dose IL-2 in Multiple Myeloma Patients

Biohaven Pharmaceuticals, Inc.

Phase 1 Completed
7 enrolled
Other hematologic neoplasmPlasma cell

Multiple Myeloma, Hematologic Neoplasms

NCT00640796 2014-04-24

Pilot Study of Expanded, Donor Natural Killer Cell Infusions for Refractory Non-B Lineage Hematologic Malignancies and Solid Tumors

St. Jude Children's Research Hospital

Phase 1 Completed
22 enrolled
LymphoidMyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Hematologic Neoplasms, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

NCT00697671 2013-07-16

Pilot Study of Haploidentical Natural Killer Cell Infusions for Poor Prognosis Non-AML Hematologic Malignancies

St. Jude Children's Research Hospital

Phase 1 Completed
48 enrolled
LymphoidMyeloidOther hematologic neoplasm

Lymphoma, Non-Hodgkin, Myelodysplastic Syndromes, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Hematologic Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Leukemia, Myelomonocytic, Juvenile

Data powered by HemOnc (CC BY 4.0) Colophon âš¡